Detailed data from the phase ii crenezumab alzheimer's prevention initiative study in autosomal dominant alzheimer's disease presented at aaic

Lausanne, switzerland, aug. 02, 2022 (globe newswire) -- ac immune sa (nasdaq: aciu), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its partners presented the first quantitative data from the alzheimer's prevention initiative (api) autosomal dominant alzheimer's disease (adad) colombia trial during a focused topic session at the alzheimer's association international conference (aaic). the study evaluated the potential of the anti-amyloid beta antibody crenezumab to slow or prevent alzheimer's disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset alzheimer's disease.
ACIU Ratings Summary
ACIU Quant Ranking